Duke Cancer Institute physicians and the Prostate Health Education Network (PHEN) present a virtual session to learn about clinical trial opportunities available at Duke.
Duke Cancer Institute clinical trials will be presented and discussed by the speakers identified below:
PROMISE REGISTRY: The purpose of the PROMISE registry is to learn more about the role genes play in improving outcomes for prostate cancer patients. Knowing this information could make a big difference in the type of treatment available to you “now, and in the future.” Participants will receive a free genetic test.
PREDICT Radiation Therapy (RT): The GU009 (PREDICT RT) clinical trial is a phase III randomized clinical trial conducted by NRG Oncology that aims to evaluate the efficacy of genomic testing in predicting the response to radiation therapy in patients with prostate cancer. The trial focuses on identifying genetic biomarkers that can be used to determine which patients will benefit the most from radiation therapy and which patients may not benefit from the treatment.
PSMAddition: The PSMAddition clinical trial aims to evaluate the efficacy and safety of a therapy called Pluvicto (PSMA-Lu177) in men with metastatic hormone-sensitive prostate cancer. This treatment uses a targeted type of radiation to attack cancer cells that express a protein known as PSMA. The trial will compare the effectiveness of the new treatment plus standard of care, which includes androgen receptor pathway inhibitors and androgen deprivation therapy, to standard of care alone. By assessing the benefits and risks of this new treatment, the results of this trial will provide valuable insights to doctors and patients regarding the management of metastatic hormone-sensitive prostate cancer.
Speakers:
Keith Crawford, MD, PhD
Director of Clinical Trials and Patient Education at PHEN
Andrew Armstrong, MD, MSc
Medical Oncologist at Duke Cancer Institute
Daniel George, MD
Medical Oncologist at Duke Cancer Institute
Leave a Reply